Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
– Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute
– No adverse reactions observed, and study can continue as planned
Related news for (CRPOF)
- Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
- Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company